Dithranol
Brand names: Dithrocream, Micanol
Dithranol (anthralin) is a topical antiproliferative agent used for chronic plaque psoriasis, often as short-contact therapy.
Adult dose
Dose adjustments
The SPC gives no renal dose adjustment (topical product).
The SPC gives no hepatic dose adjustment (topical product).
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Acute pustular psoriasis or presence of inflammation of skin, including folliculitis (§4.3)
- Erythroderma (§4.3)
- Hypersensitivity to dithranol or any other component of Micanol (§4.3)
Side effects
- Frequent: perilesional erythema and burning, lesional burning (usually mild or moderate); usually lessen after one or two weeks of treatment (§4.8)
- Rare: allergic reaction (skin rash) (§4.8)
- Staining of treated and surrounding skin (disappears within 1 to 2 weeks after the end of treatment); may temporarily discolour fingernails or grey or white hair; may stain fabrics (§4.8)
- Accidental eye contact: severe conjunctivitis, keratinitis or corneal opacity may result (§4.4)
Interactions
- Photosensitising medications: concurrent use with dithranol may enhance their photosensitising effects (§4.5)
- Propylene glycol containing drugs: dithranol would be oxidised and inactivated (§4.5)
- Withdrawal of long-term steroids in psoriasis may cause a rebound phenomenon; leave an interval of one to two weeks between stopping long-term steroids and starting Micanol, using a bland emollient meanwhile (§4.5)
- Use with caution if potent steroids have been administered recently (§4.4)
Monitoring
- Excessive redness or burning: reduce frequency or concentration, or discontinue; irritation is more likely with higher concentrations (§4.4)
- Sensitivity reactions, especially on normal skin surrounding the plaque site: discontinue use (§4.4)
- Do not apply to the face, mucous membrane, genitalia or intertriginous skin, or to blistered, raw or oozing skin; keep away from eyes (wash with plenty of lukewarm water if contact occurs) (§4.4)
- Wash hands thoroughly after use (§4.4)
- If the skin is irritated after progressing to 3%, revert to 1% cream (§4.2)
Clinical monograph
How it works
It reduces the excessive epidermal proliferation seen in psoriasis, with effects linked to inhibition of keratinocyte turnover and generation of reactive oxygen species in the skin.
Prescribing in practice
- Dithranol is irritant and can burn normal skin, so apply it carefully to plaques only and protect surrounding healthy skin, washing it off after the prescribed contact time.
- It stains skin, hair, clothing, bedding and surfaces, which limits acceptability and adherence.
- Avoid use on the face, flexures, genitals and acutely inflamed or unstable psoriasis.
Monitoring
Monitor clinically for plaque response and for irritation or burning of surrounding normal skin.
Counselling the patient
- Apply only to the thickened plaques, keep it off normal skin, and wash it off after the time you have been told.
- Expect staining of skin, hair, clothes and the bath; protect surfaces and use older bedding and towels.
- Stop and seek advice if the surrounding skin becomes sore or burnt.
Evidence & guidelines
Dithranol short-contact therapy is a long-established treatment for chronic plaque psoriasis supported by NICE psoriasis guidance.
Reference: SmPC Dithrocream; BAD Psoriasis Guideline 2017 (updated 2022); NICE CG153 (Psoriasis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD